Ondansetron: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Ondansetron. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Diarrhea | 44% |
| Pyrexia | 41% |
| Headache | 25% |
| Fever | 8% |
| Akalhisia | 6% |
| Reactions* | 5% |
| Paresthesia | 2% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Efficacy of the 32 mg single dose beyond 24 hours in these patients has not been established. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron injection, USP is recommended even where the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic ondansetron injection, USP and experience nausea and/or vomiting postoperatively, ondansetron injection, USP may be given to prevent further episodes (see CLINICAL TRIALS ).
Medical disclaimer: Always consult a qualified healthcare professional about any medication.